Abstract: A method and device for treating human intervertebral disc herniations using an endoscopic procedure. An access port is opened into and through the annulus of a disc to remove nucleus pulposus. Laser light fibers may then be passed through an endoscopic guide tube to anneal the inner surface of the disc annulus. Next, a balloon assembly with a valve is placed via the guide tube into the created disc space. The balloon is filled with a fluid to occupy the disc interspace or to maintain some degree of distraction of the created disc space. Post surgery, after fibrocollagenous tissue has grown into the disc space, a second endoscopic procedure is performed to remove the balloon assembly. Fluid is removed to collapse the balloon structure and then removed via the guide tube. The ingrowth of fibrocollagenous tissue will continue to fill the void formerly occupied by the balloon structure. The minimally invasive procedure of the invention allows for short term recovery and early return to normal activity.

Abstract: A method and device for treating human intervertebral disc herniations using an endoscopic procedure. An access port is opened into and through the annulus of a disc to remove nucleus pulposus. Laser light fibers may then be passed through an endoscopic guide tube to anneal the inner surface of the disc annulus. Next, a balloon assembly with a valve is placed via the guide tube into the created disc space. The balloon is filled with a fluid to occupy the disc interspace or to maintain some degree of distraction of the created disc space. Post surgery, after fibrocollagenous tissue has grown into the disc space, a second endoscopic procedure is performed to remove the balloon assembly. Fluid is removed to collapse the balloon structure and then removed via the guide tube. The ingrowth of fibrocollagenous tissue will continue to fill the void formerly occupied by the balloon structure. The minimally invasive procedure of the invention allows for short term recovery and early return to normal activity.

Abstract: This invention discloses organoleptically acceptable formulations containing non-solubilized S(+) 1,8-diethyl-1,3,4,9-tetrahydropyrano?3,4-b!indole-1-acetic acid, preferably with an acidic component, also known as S(+)etodolic acid or S(+)etodolac.

Abstract: This invention discloses organoleptically acceptable formulations containing S(+)-2-(p-isobutylphenyl)-propionic acid, also known as S(+) ibuprofen.

Abstract: Novel topical anesthetic compositions containing high concentrations of benzocaine in a micronized powder form suspended in an emollient vehicle.

Abstract: There are provided gastric cytoprotective exogenously acidified aluminum hydroxide antacid compositions which are formed by acidifying, for example, commercial liquid antacid suspensions containing aluminum hydroxide, antacid powders or solids containing aluminum hydroxide, or aluminum hydroxide gel, to the point where the aluminum hydroxide is solubilized. The solutuions may be formulated into liquid dosage forms or spray dried and formulated into solid dosage forms.

Abstract: A therapeutic taste-neutral powder form of ibuprofen obtained by spray-drying a suspension of colloidal silica in a lower alkanol solution of ibuprofen and cellulose acetate phthalate.

Abstract: A therapeutic taste-neutral powder form a ibuprofen obtained by spray-drying a suspension of colloidal silica in a lower alkanol solution of ibuprofen and a cellulose material such as ethyl cellulose, hydroxyethyl cellulose and hydroxypropylmethyl cellulose.

Abstract: A therapeutic taste-neutral powder form of acetaminophen obtained by spray-drying a suspension of colloidal silica in a lower alkanol solution of acetaminophen and ethyl cellulose.

Abstract: An aqueous antacid composition of magaldrate gel and a process for preparing same are described by the invention. The composition is prepared from and contains precipitated and undried magaldrate gel and a fluidizing of a first and second fluidizer. On fluidizer is provided by an aluminum hydroxide gel having colloidal properties and the second by a pharmaceutically acceptable citrate ion source including citric acid. The process and composition are characterized in providing a fluid, resuspendible, pharmaceutically elegant suspension possessing high antacid capacity and stability at even elevated magaldrate concentrations in addition to the ability to fluidize stiff, paste-like magaldrate gel cakes.

Abstract: An rehydratable antacid composition of magaldrate gel and a process for preparing same are described by the invention. The composition is prepared from and contains precipitated and undried magaldrate gel, a polyhydric alcohol and fluidizing amounts of a first and second fluidizer. One fluidizer is provided by an aluminum hydroxide gel having colloidal properties and the second by a pharmaceutically acceptable citrate ion source including citric acid. The process and composition are characterized in providing rehydratable antacid composition which when admixed with water forms a fluid, resuspendible, pharmaceutically elegant suspension possessing high antacid capacity and stability at even elevated magaldrate concentrations in addition to the ability to fluidize stiff, paste-like magaldrate gel cakes.

Abstract: Therapeutic liquid oral dosage formulations of propranolol hydrochloride are provided which contain lecithin and/or a basic amino acid to impart taste masking characteristics and/or contain a basic amino acid to impart anesthesia masking characteristics.

Abstract: A prolonged release drug dosage form for the treatment of bovine mastitis, specifically suited for dry cow treatment, consists of an antimicrobial agent dispersed in a matrix of a low molecular weight polyester of glycolic and lactic acids, and shaped as a cylindrical bougie for facile insertion into the teat canal. Said polyester erodes by hydrolysis in the bioenvironment, providing a continuous release of the medication throughout the desired duration of the treatment. The low molecular weight polyesters have a glycolic acid content of about 60 to 80 mole percent, a lactic acid content of about 20 to 40 mole percent, and a molecular weight less than 2000.